Ascelia Pharma AB (publ)
Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment o… Read more
Ascelia Pharma AB (publ) (ACE) - Net Assets
Latest net assets as of September 2025: Skr114.40 Million SEK
Based on the latest financial reports, Ascelia Pharma AB (publ) (ACE) has net assets worth Skr114.40 Million SEK as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr136.41 Million) and total liabilities (Skr22.01 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Skr114.40 Million |
| % of Total Assets | 83.86% |
| Annual Growth Rate | 0.21% |
| 5-Year Change | -66.56% |
| 10-Year Change | N/A |
| Growth Volatility | 59.49 |
Ascelia Pharma AB (publ) - Net Assets Trend (2016–2024)
This chart illustrates how Ascelia Pharma AB (publ)'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Ascelia Pharma AB (publ) (2016–2024)
The table below shows the annual net assets of Ascelia Pharma AB (publ) from 2016 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | Skr78.94 Million | +6.21% |
| 2023-12-31 | Skr74.33 Million | -58.90% |
| 2022-12-31 | Skr180.86 Million | -41.25% |
| 2021-12-31 | Skr307.83 Million | +30.41% |
| 2020-12-31 | Skr236.06 Million | -0.42% |
| 2019-12-31 | Skr237.06 Million | -14.13% |
| 2018-12-31 | Skr276.07 Million | +147.09% |
| 2017-12-31 | Skr111.73 Million | +43.98% |
| 2016-12-31 | Skr77.60 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Ascelia Pharma AB (publ)'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 64466000000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | Skr97.19 Million | 123.12% |
| Other Comprehensive Income | Skr974.00K | 1.23% |
| Other Components | Skr721.75 Million | 914.26% |
| Total Equity | Skr78.94 Million | 100.00% |
Ascelia Pharma AB (publ) Competitors by Market Cap
The table below lists competitors of Ascelia Pharma AB (publ) ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Duck Yang Ind
KO:024900
|
$25.35 Million |
|
Avadh Sugar & Energy Limited
NSE:AVADHSUGAR
|
$25.36 Million |
|
Community Bancorp of Santa Maria
OTCQX:CYSM
|
$25.37 Million |
|
Northeast Group Berhad
KLSE:0325
|
$25.41 Million |
|
Cuulong Fish JSC
VN:ACL
|
$25.35 Million |
|
Turker Proje Gayrimenkul Ve Yatirim Gelistirme AS
IS:TURGG
|
$25.32 Million |
|
Multicampus Corporation
KQ:067280
|
$25.32 Million |
|
Haulotte Group SA
PA:PIG
|
$25.32 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Ascelia Pharma AB (publ)'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 74,328,000 to 78,944,000, a change of 4,616,000 (6.2%).
- Net loss of 80,029,000 reduced equity.
- Share repurchases of 105,324,000 reduced equity.
- New share issuances of 105,324,000 increased equity.
- Other comprehensive income increased equity by 303,000.
- Other factors increased equity by 84,342,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Skr-80.03 Million | -101.37% |
| Share Repurchases | Skr105.32 Million | -133.42% |
| Share Issuances | Skr105.32 Million | +133.42% |
| Other Comprehensive Income | Skr303.00K | +0.38% |
| Other Changes | Skr84.34 Million | +106.84% |
| Total Change | Skr- | 6.21% |
Book Value vs Market Value Analysis
This analysis compares Ascelia Pharma AB (publ)'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.05x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 0.87x to 2.05x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | Skr3.43 | Skr3.00 | x |
| 2017-12-31 | Skr4.94 | Skr3.00 | x |
| 2018-12-31 | Skr16.08 | Skr3.00 | x |
| 2019-12-31 | Skr10.87 | Skr3.00 | x |
| 2020-12-31 | Skr8.99 | Skr3.00 | x |
| 2021-12-31 | Skr9.34 | Skr3.00 | x |
| 2022-12-31 | Skr5.20 | Skr3.00 | x |
| 2023-12-31 | Skr2.20 | Skr3.00 | x |
| 2024-12-31 | Skr1.46 | Skr3.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Ascelia Pharma AB (publ) utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -101.37%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.79x
- Recent ROE (-101.37%) is below the historical average (-56.97%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | -21.83% | 0.00% | 0.00x | 1.04x | Skr-35.56 Million |
| 2018 | -13.45% | 0.00% | 0.00x | 1.04x | Skr-64.74 Million |
| 2019 | -16.83% | 0.00% | 0.00x | 1.06x | Skr-63.61 Million |
| 2020 | -41.81% | 0.00% | 0.00x | 1.08x | Skr-122.30 Million |
| 2021 | -40.90% | 0.00% | 0.00x | 1.08x | Skr-156.69 Million |
| 2022 | -72.56% | 0.00% | 0.00x | 1.21x | Skr-149.31 Million |
| 2023 | -147.03% | 0.00% | 0.00x | 1.17x | Skr-116.72 Million |
| 2024 | -101.37% | 0.00% | 0.00x | 1.79x | Skr-87.92 Million |
Industry Comparison
This section compares Ascelia Pharma AB (publ)'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $46,934,875
- Average return on equity (ROE) among peers: -138.95%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Ascelia Pharma AB (publ) (ACE) | Skr114.40 Million | -21.83% | 0.19x | $25.35 Million |
| 2cureX AB (2CUREX) | $20.24 Million | -15.50% | 0.13x | $1.38 Million |
| Abliva AB (ABLI) | $63.04 Million | -23.59% | 0.13x | $46.60 Million |
| AcouSort AB (ACOU) | $20.11 Million | -65.68% | 1.12x | $4.82 Million |
| Active Biotech AB (ACTI) | $162.30 Million | -107.35% | 0.93x | $3.55 Million |
| Alzinova AB (ALZ) | $29.39 Million | -8.53% | 0.08x | $4.19 Million |
| AlzeCure Pharma (ALZCUR) | $110.75 Million | -64.44% | 0.06x | $12.56 Million |
| Annexin Pharmaceuticals AB (ANNX) | $20.64 Million | -216.80% | 0.22x | $4.92 Million |
| Alligator Bioscience AB (ATORX) | $6.86 Million | -748.65% | 15.13x | $723.60K |
| Biosergen AS (BIOSGN) | $-10.92 Million | 0.00% | 0.00x | $2.76 Million |